Eli Lilly Unveils Key Insights at the American Diabetes Association's 85th Scientific Sessions
On May 29, 2025, Eli Lilly and Company made an impactful announcement regarding its presentations at the upcoming 85th American Diabetes Association (ADA) Scientific Sessions, which is set to take place from June 20-23 in Chicago. This year’s event marks an essential gathering for the diabetes community, where cutting-edge research and innovative treatments will be highlighted. Among the significant topics of discussion will be studies on several of Lilly's investigational diabetes therapies including orforglipron, insulin efsitora alfa, and tirzepatide, with varying presentations that aim to provide new insights into diabetes management.
Lilly plans to present data from its groundbreaking research, encompassing various novel diabetes treatments. Here are a few highlights:
Orforglipron
One of the standout presentations will focus on orforglipron, an investigational oral GLP-1 receptor agonist. The findings from the ACHIEVE-1 Phase 3 trial will be shared during an ADA-sponsored symposium. This trial evaluated the safety and efficacy of orforglipron in adults with type 2 diabetes who struggled to maintain adequate glycemic control through diet and exercise alone.
Insulin Efsitora Alfa
Another crucial aspect of Lilly's presentation will be centered around insulin efsitora alfa, an investigational basal insulin designed for once-weekly administration. During a dedicated symposium, Lilly will unveil results from three Phase 3 trials (QWINT-1, QWINT-3, and QWINT-4), which explore the impact of efsitora in adults living with type 2 diabetes.
Tirzepatide
Lilly will further discuss the promising outcomes of tirzepatide, an injectable medication also known as Zepbound and Mounjaro. Various studies will be presented, including data on its effects on kidney function in individuals with obesity and prediabetes, its efficacy in managing weight loss over extended periods, and head-to-head comparisons with other treatments. These presentations are highly anticipated and will shed light on how tirzepatide works in patients struggling with obesity and related conditions.
In addition to the scientific presentations, Lilly will also hold an investor event on June 22 at 6:30 PM CDT, providing insights into their cardiometabolic health portfolio and discussing key findings from the ADA sessions. This live event will be accessible via webcast on Lilly’s investor relations website, ensuring that interested parties can participate even remotely. Following the event, a replay will be made available for those unable to attend the live session.
Eli Lilly has been at the forefront of diabetes care for nearly a century, diligently working to offer innovative solutions that improve the quality of life for those managing diabetes. With a portfolio encompassing a multitude of investigational treatments, they are committed to addressing the unique needs of patients through ongoing research and clinical trials. The company aims to utilize biotechnology and medical advancements to transform diabetes management and, ultimately, provide better healthcare outcomes globally.
Stay tuned as Eli Lilly continues to unveil critical data that could redefine the treatment landscape for diabetes at this year’s ADA Scientific Sessions. For those interested in the details of the presentations, the ADA conference promises to be a pivotal gathering of healthcare professionals, researchers, and individuals dedicated to combating diabetes effectively.
Key Presentations from Lilly
Lilly plans to present data from its groundbreaking research, encompassing various novel diabetes treatments. Here are a few highlights:
Orforglipron
One of the standout presentations will focus on orforglipron, an investigational oral GLP-1 receptor agonist. The findings from the ACHIEVE-1 Phase 3 trial will be shared during an ADA-sponsored symposium. This trial evaluated the safety and efficacy of orforglipron in adults with type 2 diabetes who struggled to maintain adequate glycemic control through diet and exercise alone.
Insulin Efsitora Alfa
Another crucial aspect of Lilly's presentation will be centered around insulin efsitora alfa, an investigational basal insulin designed for once-weekly administration. During a dedicated symposium, Lilly will unveil results from three Phase 3 trials (QWINT-1, QWINT-3, and QWINT-4), which explore the impact of efsitora in adults living with type 2 diabetes.
Tirzepatide
Lilly will further discuss the promising outcomes of tirzepatide, an injectable medication also known as Zepbound and Mounjaro. Various studies will be presented, including data on its effects on kidney function in individuals with obesity and prediabetes, its efficacy in managing weight loss over extended periods, and head-to-head comparisons with other treatments. These presentations are highly anticipated and will shed light on how tirzepatide works in patients struggling with obesity and related conditions.
Special Investor Event
In addition to the scientific presentations, Lilly will also hold an investor event on June 22 at 6:30 PM CDT, providing insights into their cardiometabolic health portfolio and discussing key findings from the ADA sessions. This live event will be accessible via webcast on Lilly’s investor relations website, ensuring that interested parties can participate even remotely. Following the event, a replay will be made available for those unable to attend the live session.
About Eli Lilly
Eli Lilly has been at the forefront of diabetes care for nearly a century, diligently working to offer innovative solutions that improve the quality of life for those managing diabetes. With a portfolio encompassing a multitude of investigational treatments, they are committed to addressing the unique needs of patients through ongoing research and clinical trials. The company aims to utilize biotechnology and medical advancements to transform diabetes management and, ultimately, provide better healthcare outcomes globally.
Stay tuned as Eli Lilly continues to unveil critical data that could redefine the treatment landscape for diabetes at this year’s ADA Scientific Sessions. For those interested in the details of the presentations, the ADA conference promises to be a pivotal gathering of healthcare professionals, researchers, and individuals dedicated to combating diabetes effectively.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.